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Abstract
Aneurysmal subarachnoid hemorrhage (SAH) is a severe life-threatening dis-
ease and an important source of neurological disability. Therapeutic interventions 
over the last few decades have repeatedly failed to improve functional outcome after 
SAH; however, resolution of inflammation has largely been ignored as a potential 
therapeutic target. The omega-3 fatty acids (FAs), eicosapentaenoic acid (EPA), 
and docosahexaenoic acid (DHA) are the precursors of key mediators involved 
in resolution of inflammation and endogenous neuroprotection. EPA also plays a 
major role in microvascular function, and DHA accretion in the brain is crucial for 
normal neuronal function. Although considerable loss of brain DHA has been iden-
tified in SAH patients, the pathological significance of this process has also been 
overlooked. Current Western diets provide insufficient amounts of omega-3 FAs to 
compensate for the loss of brain DHA following SAH. Here, we review the rationale 
for future clinical trials of omega-3 FAs in SAH. Furthermore, the potential role 
of defective resolution of inflammation in the growth and rupture of intracranial 
aneurysms is inferred from recent findings in atherosclerosis and nutrition. The 
novel concepts of resolution of inflammation and endogenous neuroprotective 
signaling may open new avenues for public health interventions and innovative 
research in intracranial aneurysms and SAH.
Keywords: fish oil, inflammation, intracranial aneurysms, omega-3 fatty acids, 
pharmaconutrition, subarachnoid hemorrhage, translational approach
1. Introduction
Aneurysmal subarachnoid hemorrhage (SAH) is a complex condition with an 
intricate and poorly understood pathophysiology. Increasing evidence strongly 
suggests that neuroinflammation plays a critical role after SAH, but conventional 
anti-inflammatory treatments have failed to improve clinical outcome [1]. Clinical 
research on SAH has mainly focused on delayed cerebral ischemia (DCI); however, 
DCI does not encompass the entire spectrum of pathological and clinical manifesta-
tions of SAH [2–4]. Although cerebral infarction is associated with poor clinical 
outcome and death after SAH, a significant proportion of SAH patients without 
cerebral infarction suffer from cognitive deficits and mood disorders and a reduced 
ability for activities of daily living and working, even in the long term [5, 6]. The 
absence of a close correlation between DCI and functional recovery indicates an 
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ongoing pathophysiological process has been overlooked in SAH. The failure of 
the recent major NEWTON 2 clinical trial, of sustained intraventricular release of 
nimodipine, is the latest in a series of unsuccessful phase 3 randomized controlled 
trials (RCTs) to improve clinical outcome after SAH and further reinforces the need 
to identify novel therapeutic strategies [7, 8].
Nutrition is essential to human health, and appropriate nutritional support is 
currently considered a standard of care for critically ill patients. Malnutrition—
including depletion of essential micronutrients—frequently occurs among critically 
ill patients and is associated with an increased risk of morbimortality [9]. However, 
the clinical relevance of key nutrient deficiencies in acute neurological illnesses 
has not been thoroughly investigated. EPA and DHA are essential constituents 
of endothelial and neuronal membranes, respectively, and also the precursors of 
key mediators involved in resolution of inflammation and endogenous neuropro-
tection [10, 11]. Although massive loss of brain DHA in SAH patients was first 
reported over 15 years ago, the pathological significance of this process and the 
role of inflammation resolution following SAH have largely been ignored [11, 12]. 
Therapeutic interventions aimed at stimulating inflammation resolution and recov-
ering the homeostasis of the brain and other vital organs after SAH could improve 
patients’ functional outcome [13].
This chapter provides an overview of the potentially harmful consequences 
of selective deficiency of omega-3 FAs on brain structure and function in SAH 
patients. Moreover, given the possible clinical relevance to SAH and the growth and 
rupture of intracranial aneurysms (IAs), we provide a detailed discussion of recent 
findings on the role of omega-3 FAs in resolution of inflammation, with a focus on 
brain homeostasis.
2. Role of omega-3 FAs in resolution of acute inflammation
Remarkable progress in our understanding of the pathophysiology of acute 
inflammation has been achieved through basic science over the last 20 years. 
Resolution of acute inflammation is now considered to be an active biochemical 
process that is required to enable tissues to restore normal structure and function 
following an injury [14]. Interference with the resolution phase of acute inflamma-
tion may result in necrosis, chronic inflammation, fibrosis, and organ dysfunction. 
The resolution process is triggered at the beginning of inflammation by a temporal 
switch in lipid mediator classes, which is induced by cross talk between cells of the 
innate immune system and other cells in the inflammatory microenvironment [11].
A diverse range of biologically active pro-resolving and anti-inflammatory 
mediators are synthetized by complex pathways that involve several enzymes, 
including cyclooxygenase 2 (COX-2), cytochrome P450s and several lipoxygenases 
(LOX). The majority of these endogenous mediators are derived from the long-
chain omega-3 fatty acids (FAs) EPA and DHA and are members of the specialized 
pro-resolving mediator (SPM) superfamily [15]. SPMs represent an essential bio-
chemical interface between inflammation and tissue repair and regeneration. The 
resolution of inflammation is a highly orchestrated adaptive process that depends 
on both the availability of SPMs precursors and the efficiency of the related biosyn-
thetic pathways.
2.1 Specialized pro-resolving mediators
Each endogenous lipid mediator is structurally distinct and possesses specific 
biological functions which have been extensively studied in diverse experimental 
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models. EPA is the precursor of the E-series resolvins (RvEs), which contains four 
main mediators (RvE1-RvE3 and 18-HEPE). DHA is the precursor of the D-series 
resolvins (RvDs), which contains six mediators (RvD1-RvD6), as well as the protec-
tins (PD1-PDX) and the maresins (MaR1-MaR2); DHA derivatives are also known 
as docosanoids [15].
SPMs are active at pico-nanogram ranges and exert pleiotropic actions at the 
inflammatory microenvironment. SPMs stimulate the clearance of bacteria, dead cells, 
and debris that is required during tissue repair. SPMs also reduce leukocyte transendo-
thelial migration, platelet activation, and production of inflammatory cytokines, thus 
providing multi-organ protection. The maresins (macrophage mediators in resolving 
inflammation) exert potent phagocyte-directed actions that include phenotypic 
conversion of proinflammatory macrophages into macrophages that suppress inflam-
mation and promote tissue regeneration [16]. Collectively, SPMs actively promote 
resolution of inflammation and recovery of tissue homeostasis [15]. Interestingly, 
resolution of systemic inflammation appears to have its counterpart in the CNS repre-
sented by different DHA-derived endogenous mediators (see Section 5.1).
The biosynthetic pathways that generate SPMs are clinically relevant and 
have been comprehensively studied [15, 16]. Drugs that inactivate the enzymes 
involved in SPM biosynthesis, such as selective COX-2 inhibitors and certain 
LOX inhibitors, delay the return to homeostasis and are considered resolution 
antagonists. Importantly, selective COX-2 inhibitors were synthesized before 
the identification of inflammation resolution pathways and are currently 
widely used as anti-inflammatory agents. Aspirin and statins also modify 
COX-2 by acetylation and S-nitrosylation, respectively, which results in genera-
tion of longer-acting SPM R-epimers. Thus, aspirin and statins are resolution 
agonists [15, 16].
3. Incorporation and transport of omega-3 FAs
Incorporation and transport of omega-3 FAs have been comprehensively 
described; here, we focus on the clinically relevant aspects [10, 17, 18]. Several 
studies have consistently shown that in vivo conversion of alpha linolenic acid 
(ALA), the short-chain omega-3 FAs from vegetable origin, to its bioactive 
long-chain derivatives (EPA and DHA) is very low in humans. In addition, the 
metabolism of omega-6 and omega-3 FAs is tightly linked, and thus a high dietary 
intake of omega-6 FAs further reduce the conversion of ALA to EPA and DHA 
and their biological effects. The body has also a limited capacity to store long-
chain omega-3 FAs; only very small amounts of EPA and DHA are present in 
adipose tissue, and the brain retains DHA for its own function. Thus, providing 
preformed EPA and DHA is the most efficient method of increasing the concen-
trations of EPA and DHA in plasma and tissues.
EPA and DHA are incorporated into different blood lipid fractions after absorp-
tion by the gastrointestinal tract or after release from intravenously infused fish 
oil-based lipid emulsions (FOLE). These lipid fractions reflect the diverse means by 
which FAs are transported in the circulation and execute their physiological func-
tions. The fractions incorporated in the phospholipid coat of plasma lipoproteins 
and plasma nonesterified FAs (NEFAs) are considered transport pools. Notably, the 
NEFA pool seems to be the main DHA plasma fraction that supplies the brain. The 
NEFA pool also represents a direct source of FAs to cells for generation of SPMs, as 
this pool readily transfers to inflammatory tissue via edema formation [19]. The FAs 
fraction incorporated in peripheral blood mononuclear cells (PBMCs) represents a 
functional pool due to the crucial roles of PBMCs in inflammation.
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3.1 Omega-3 index
The EPA and DHA content of red blood cells (RBCs) membrane which can be 
quantified by a specific and standardized analytical procedure—the HS-Omega-3 
Index® methodology—reliably reflects the omega-3 FAs content of several tissues 
[20]. This omega-3 index has been increasingly utilized as a surrogate marker of 
omega-3 status. Long-term intake of EPA and DHA is the main predictor of the 
omega-3 index, but other factors influence its variability. Acute supplementation 
of omega-3 FAs does not modify the omega-3 index, as expected given the long 
lifetime of RBCs (100–120 days). In terms of clinical relevance, strong inverse 
correlations have been observed between the omega-3 index and cardiovascular 
morbimortality, particularly sudden cardiac death, as well as depression [21–23].
4. Role of EPA in microvascular thromboinflammation
Microvascular inflammation is an early event in the pathogenesis of atherosclerosis 
and other inflammatory conditions and is inextricably linked to microthrombosis [24]. 
Eicosanoid metabolism and leukocyte-endothelial interactions are interrelated pro-
cesses and in turn are major drivers of thromboinflammation [25, 26]. Inflammation 
stimulates eicosanoid synthesis and expression of cell-surface adhesion molecules 
through upregulation of the nuclear factor kappa B (NF-kB), a master transcription 
factor necessarily involved in the inflammatory response.
Most eicosanoids derived from the long-chain omega-6 FAs arachidonic acid 
(ARA), including prostaglandins, leukotrienes, and thromboxanes, are potent vaso-
constrictors, platelet activators, and leukocyte chemotactic factors. Moreover, the 
expression of cell-surface adhesion molecules on endothelial and inflammatory cells 
is essential for leukocyte-endothelial interactions; rolling and adhesion on vascular 
surfaces are the first step in the recruitment of circulating leukocytes or platelets to 
sites of thromboinflammation [27].
EPA incorporated in the membrane phospholipids of inflammatory cells can 
modulate eicosanoid metabolism by replacing ARA as an eicosanoid precursor 
[25]. EPA-derived eicosanoids are significantly less potent than those derived from 
ARA, and nonesterified EPA can also directly inhibit the production of eicosanoids 
from ARA. In addition, EPA has been shown to decrease the expression of several 
cell-surface adhesion molecules on inflammatory cells. EPA appears to elicit these 
pleiotropic effects by modulating the activity of the NF-kB.
Additionally, recent mechanistic studies have shown that minor changes in the 
EPA content of endothelial membranes may markedly alter the biophysical proper-
ties of the membrane [28]. Furthermore, changes in membrane fluidity, thickness, 
and deformability induced by modifications to lipid dynamics and/or structural 
organization can profoundly impact endothelial function [29]. Given the intimate 
association between brain capillary pericytes and endothelial cells, it would not be 
surprising if EPA also incorporates into pericyte cell membranes and potentiates the 
function of these cells as regulators of brain homeostasis [30, 31].
5. Unique function of DHA in the brain
DHA is widely distributed throughout the human body in membrane phospho-
lipids and is particularly abundant in neural tissues such as the brain and retina 
[10]. DHA represents 30–40% of the fatty acid content of the gray matter in the 
cortex and is absorbed into the brain by a specific transporter that is found in 
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the endothelium of the blood-brain barrier (BBB) microvasculature [32, 33]. The 
functional significance of selective enrichment of DHA in neural tissues has been 
actively researched over the last few decades. DHA possesses unique biophysical 
and biochemical characteristics that make it particularly suitable for brain and 
retinal membranes. DHA has been highly conserved during evolution and is pres-
ent throughout the entire spectrum of living organisms [34]. DHA has even been 
suggested to be a major determinant for evolution of the modern hominid brain 
due to its unique encephalization potential [35].
DHA is an essential component of neuronal membrane architecture and com-
position and promotes selective accumulation of phosphatidylserine (PS), a crucial 
phospholipid involved in intracellular signaling [36]. PS participates in the signal-
ing events of several key enzymes, including protein kinase C, Raf-1 kinase, and 
Akt, which play essential roles in cell proliferation, differentiation, and survival. 
Thus, DHA significantly modulates the activity of essential cellular kinases in 
neuronal cells.
5.1 DHA and endogenous neuroprotective signaling
In addition to its function as a unique building block of cell membranes, DHA is 
also a precursor for docosanoids and other bioactive endogenous derivatives in the 
neural tissue [37]. The number of recently identified DHA derivatives in neural tis-
sue is increasingly growing and includes neuroprotectin D1 (NPD1), synaptamide, 
endocannabinoid epoxides, and elovanoids [38–40]. Collectively, the potent 
bioactive properties of these DHA derivatives contribute to preservation of normal 
neuronal function, tissue homeostasis, and neuronal survival [37–41]. In addition, 
the DHA derivatives exert a range of potent neuroprotective properties that include 
inhibition of proinflammatory gene expression and leukocyte infiltration. A strik-
ing hallmark of the DHA derivatives is their ability to potentiate microglial polar-
ization from a proinflammatory phenotype to a surveillance-repair state and reduce 
NF-kB-mediated expression of inflammatory cytokines in the brain. Moreover, 
DHA derivatives contribute to BBB integrity and are neurogenic and synaptogenic 
[38, 42]. Thus, the DHA derivatives seem to be key mediators of the resolution of 
inflammation and recovery of homeostasis in the CNS microenvironment.
5.2 DHA and neurovascular unit
The concept of neurovascular unit emphasizes the intimate relationship 
between the brain and its vessels, particularly the coupling between neural activ-
ity and cerebral blood flow [43]. Although the role of DHA neurolipidomics in 
neurovascular coupling appears to be underestimated, substantial experimental 
evidence suggests that the morphologic and functional integrity of the neurovas-
cular unit largely depends on high DHA enrichment [37, 40, 43]. Moreover, the 
potential role of EPA in microvascular function further supports the evolutionary 
importance of these essential nutrients to maintain efficient functional couplings 
between neural and vascular networks [28, 29]. A functional neurovascular unit 
may be crucial not only for neurovascular coupling but also for BBB integrity and 
neurogenesis.
A regular dietary supply of DHA is required to preserve normal brain and retinal 
function. Under physiologic conditions, the net DHA incorporation rate for the 
entire human brain is very low and equivalent to the net rate of DHA consumption 
by the brain (3.8 ± 1.7 mg/day) [44]. However, loss of DHA in pathological states 
or due to nutritional deficiency of omega-3 FAs may severely impair neurovascular 
integrity and have far-reaching implications on normal brain function [36].
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6. Loss of brain DHA after SAH
To date, three clinical studies have examined the loss of DHA from the brain 
after SAH. Pilitsis et al. conducted the first observational study to analyze free fatty 
acid (FFA) concentrations in cerebrospinal fluid (CSF) [12]. The concentrations of 
ARA, DHA, linoleic acid, myristic acid, oleic acid, and palmitic acid were measured 
over the first 14 days following SAH in 20 patients. A cohort of 73 patients with no 
evidence of acute neurological disease served as the control group. Compared to 
control patients, the concentrations of all FFAs tested were significantly elevated 
in CSF during the first 2 days after SAH, with a significant secondary increase in 
FAA concentrations at 8–10 days. The concentrations of DHA exhibited a biphasic 
increase and remained significantly elevated (200–600%) throughout the first 
14 days after SAH.
Increased levels of free DHA in CSF after SAH are likely to be the result of the 
cleavage of DHA from membrane phospholipids by either direct structural damage 
or an increase in phospholipase A2 activity in response to neuroinflammation. DHA 
can also be readily oxidized due to its high degree of unsaturation and excessive 
generation of free radicals following SAH [45]. Such nonenzymatic oxidation of 
DHA generates F4-neuroprostanes (F4-NPs), which represent a lipid marker of 
oxidative stress in the CNS. Two clinical studies confirmed that the concentrations 
of F4-NPs in CSF significantly increased within the first 24 hours following SAH 
compared to control patients [46, 47]. Hsieh et al. also showed the concentrations 
of F4-NPs in CSF remained significantly elevated throughout the first 10 days after 
SAH and suggested a positive correlation exists between F4-NP concentrations and 
clinical outcome at 3 months after SAH. Despite the limited number of patients 
analyzed, these studies provided valuable evidence that substantial loss of brain 
DHA occurs after SAH.
Moreover, it is highly likely that SAH may increase metabolic consumption of 
DHA though increased generation of neuroprotective derivatives. This potential 
additional source of DHA loss has not yet been evaluated but could be significant. 
Net cumulative DHA loss from the brain (DHA loss + DHA consumption) follow-
ing SAH may be massive in some cases and is likely to impose a severe burden  
on the brain.
6.1 Selective brain malnutrition
A current Western diet may provide sufficient amounts of FAs to compensate for 
the loss of other FAs, but not DHA. Current Western diets are characterized by very 
low intakes of long-chain omega-3 FAs and high intakes of other FAs, especially 
omega-6 FAs such as ARA and linoleic acid [48]. Thus, a significant imbalance 
between brain DHA loss and inadequate nutritional intake of omega-3 FAs may 
persist over the long term in SAH patients, hindering the recovery of DHA accretion 
in the brain required for normal neuronal function [35, 36].
Loss of EPA after SAH has not yet been examined; however, it is reasonable to 
assume that depletion of EPA from cerebral endothelial membranes may play a 
significant role in microvascular dysfunction after SAH. Indeed, EPA seems to have 
a more potent effect than DHA in the treatment of mood disorders, though the 
underlying mechanisms remain elusive [22].
We coined the term “selective brain malnutrition” to describe the pathological 
consequences of EPA and DHA loss following SAH on the structure and function 
of the brain. This novel hypothesis of selective brain malnutrition offers a plausible 
explanation for some of the intriguing clinical features of SAH, including diffuse 
cerebral atrophy and the frequently observed long-lasting functional sequelae, such 
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as cognitive dysfunction and mood disorders, that occur even in the absence of focal 
injury [5, 49]. Importantly, a higher omega-3 index has been associated with larger 
total brain and hippocampal volumes in observational studies in humans [50].
7. Roles of EPA and DHA in resolution of inflammation after SAH
Consensus has emerged on the pressing need to find a multipronged therapeutic 
intervention to address the various deleterious effects of early brain injury (EBI) 
after SAH [51]. Nonetheless, the loss of brain DHA after SAH is likely to be an 
unrecognized effect of EBI, and in turn loss of DHA may represent a critical event 
in the pathogenesis of secondary brain injury after SAH. Depending on the severity 
of SAH, the cumulative burden of brain DHA loss may be massive and decreases 
endogenous neuroprotective capacity in the short term [12, 36]. Thus, unresolved 
homeostatic disturbances within the cerebral microenvironment may lead to neuro-
vascular uncoupling, which may spread over the cerebral cortex in the most severe 
cases [52]. The loss of an entire series of signaling events required for maintenance 
of neurovascular network integrity may further increase the risk of focal injury, 
diffuse cerebral atrophy, and functional sequelae [37]. In this context, it is reason-
able to assume that large-artery vasospasm may paradoxically be a compensatory 
mechanism to preserve tissue oxygen availability in the presence of progressive 
microvascular failure, i.e., when capillary transit time heterogeneity substantially 
increases [3, 31]. Unresolved inflammation may also induce hyperproliferation of 
arachnoid cap cells, which increases the risk of hydrocephalus [4]. Uncontrolled 
systemic complications, such as severe cardiopulmonary dysfunction, may further 
aggravate homeostatic disturbances and have devastating consequences on brain 
function [53].
Theoretically, EPA, DHA, and their respective SPMs possess the bioactive 
capacity to counteract the major homeostatic disturbances that occur after 
SAH. EPA-RvEs could reduce thromboinflammation at the cerebral microvas-
culature by inhibiting vasoconstriction, leukocyte transendothelial migration, 
and platelet aggregation [15, 26]. DHA and its derivatives may trigger the critical 
signals required to maintain functional neurovascular coupling and cell survival 
[16, 36, 37]. DHA-induced upregulation of the enzyme heme oxygenase 1 (HO-1) 
may accelerate the clearance of subarachnoid clots and thus decrease heme-
induced cerebral inflammation [54]. SMPs may attenuate inflammation-induced 
hyperproliferation of arachnoid cap cells, further contributing to diminish the risk 
of hydrocephalus. SPMs may also provide multi-organ protection and enhance the 
immune response against infections.
Furthermore, the promising role of DHA derivatives in reducing microglial 
polarization toward an inflammatory phenotype may offer a novel approach to 
reduce the brain inflammation induced by neurosurgical trauma in surgically 
treated SAH patients [55]. Neurogenesis has also been identified in SAH patients, 
and thus DHA could represent a novel therapeutic strategy to improve neurological 
recovery by stimulating neurogenesis [56]. Moreover, subtle changes on microvas-
cular function and synaptogenesis induced by EPA and DHA may improve cogni-
tive function and mood and thus increase the likelihood of complete functional 
recovery of SAH patients.
7.1 Clinical rationale for omega-3 FAs therapy in SAH
The theoretical framework described above provides scientific rationale for 
future clinical trials of omega-3 FAs in SAH patients. The disappointing results 
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of RCTs of isolated pharmaceutical interventions in SAH could be overcome if 
a translational approach is correctly implemented [8]. In support of this notion, 
the recently published phase 3 REDUCE-IT trial provided a robust demonstration 
of the clinical efficacy and therapeutic potential of EPA to reduce cardiovascular 
events in chronic cardiovascular (CV) patients with hypertriglyceridemia [57]. 
Obviously, there are major differences between patients with chronic CV disease 
and hypertriglyceridemia and patients with SAH. Nevertheless, the consider-
able clinical benefits of EPA observed in patients with CV disease (who were 
already on statin therapy) may be due not only to the triglyceride-lowering effect 
of EPA. Interestingly, the results of the REDUCE-IT trial resemble those of the 
GISSI-Prevenzione trial conducted 20 years ago, in which a low-dose oral treatment 
of EPA plus DHA significantly reduced CV morbimortality in patients who had 
suffered a recent myocardial infarction and were already on aspirin treatment [58].
Minor changes in overall membrane FAs composition and the increase in local 
production of longer-acting SPM R-epimers after combined treatment with omega-3 
FAs and aspirin or statins are likely to mediate a wide variety of biological effects and 
have a profound impact on cellular and multi-organ function [15]. Indeed, emerging 
evidence clearly indicates a strong association between a higher omega-3 index and 
major health benefits (reduced risk of both CV and all-cause mortality) over the 
long term [21]. However, the acute and critical nature of SAH imposes a particularly 
demanding therapeutic challenge as the homeostatic disturbances in the brain and 
other vital organs must be effectively addressed in the short term. An intervention 
based exclusively on oral supplementation with omega-3 FAs is unlikely to be fully 
effective on its own in the clinical context of SAH. However, the superiority of par-
enteral administration over oral or enteral administration of omega-3 FAs has been 
reliably demonstrated in short-term interventions [17, 59]. Parenteral administra-
tion of omega-3 FAs allows rapid delivery of higher doses of EPA and DHA without 
bioavailability issues and does not depend on the patient’s clinical condition. Indeed, 
the incorporation profiles of EPA and DHA in the transport and functional pools 
after a single parenteral dose are equivalent to up to several weeks of oral supplemen-
tation. EPA and DHA appear in PBMCs as rapidly as 6 hours after a single parenteral 
dose, thus highlighting the ability of parenterally administered omega-3 FAs to easily 
reach the innate immune system [59]. The concentration of omega-3 FAs in the main 
plasmatic fraction that supplies the brain and other vital organs (the NEFA pool) also 
increases rapidly after a single parenteral dose [17, 60]. Thus, the SPM precursors EPA 
and DHA seem to be rapidly and widely available to activate resolution of inflam-
mation on demand in different organs after parenteral administration. Therefore, 
parenteral administration may be the most efficient way to deliver omega-3 FAs 
during the acute stage of SAH. This novel therapy is in accordance with the concept of 
pharmaconutrition, in which key nutrients are utilized as pharmacological agents and 
delivered in appropriate doses via the most efficient administration route [61]. Oral or 
enteral administration may be suitable for medium- or long-term treatment when the 
patient’s gastrointestinal function has completely recovered.
8. Omega-3 FAs dosage for clinical use
A regular supplementation dose for healthy subjects defined by several health 
associations worldwide is around 500–750 mg/day of EPA plus DHA and can be 
achieved by consuming a regular diet that contains two portions of fatty fish per 
week [62]. Therapeutic anti-inflammatory doses of EPA plus DHA are usually 
considered to be above 2 g/day [25]. A daily dose of at least 1 g EPA plus DHA/
day (EPA > 60% DHA) has been shown to be effective in patients with depressive 
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disorders [22]. EPA doses above 1.8 g/day seem to be required to produce clinically 
meaningful effects on endothelial and vascular function [63]. In patients with 
age-related cognitive decline, 900 mg DHA/day improved learning and memory 
function [64]. Importantly, omega-3 FAs doses can be significantly reduced by 
decreasing the dietary intake of omega-6 FAs. This fact likely explains the notably 
different dosages of EPA required to obtain beneficial outcomes in patients with 
chronic CV disease in a Japanese trial (1.8 g/day) and the REDUCE-IT trial (4 g/
day) conducted in 11 Western countries [48, 57, 63].
The therapeutic dose of parenteral fish oil (FO) to complement total parenteral 
nutrition (TPN) is of 0.1–0.2 g of FO/kg/day [59]. This dosage is equivalent to 1–2 ml/ 
kg/day of a specific FOLE that contains 10 g of FO/100 ml.
8.1 Bioavailability of omega-3 FAs oral formulations
Bioavailability refers to both the speed of absorption and the quantity of the 
substance absorbed in the gastrointestinal tract. The bioavailability of omega-3 FAs 
oral formulations should be carefully considered as it may have direct clinical impli-
cations [65]. The bioavailability of EPA and DHA depends on the chemical form 
in which they are bound (phospholipids > triglycerides > free fatty acids > ethyl 
esters) as well as their Galenic form (i.e., microencapsulation, emulsification) and 
also matrix effects (capsule ingestion with concomitant content of food, fat con-
tent in food). Galenic form and matrix effects are the most important factors that 
influence the bioavailability of EPA and DHA. Thus, administration of high-quality 
pharmaceutical formulations with fatty meals is necessary to ensure the effective-
ness of oral therapy.
9.  Experimental models and clinical interventional studies  
of omega-3 FAs in SAH
9.1 Experimental models
To date, only two preclinical studies of omega-3 FAs in experimental models of 
SAH have been published. Yin et al. suggested that pre-treatment with omega-3 FAs 
by oral gavage elicited anti-inflammatory and anti-apoptotic effects in a rat model 
of SAH [66]. Zhang et al. showed intravenous administration of DHA may prevent 
oxidative stress-induced apoptosis by improving mitochondrial dynamics in a rat 
model of SAH induced by endovascular perforation [67]. However, the scarcity 
of preclinical studies on omega-3 FAs in SAH contrasts with the large number of 
experimental studies on ischemic stroke. The effects of omega-3 FAs (or specific 
derivatives) in neural tissue have been widely examined in experimental ischemia-
reperfusion models [55, 68, 69]. These studies have consistently shown that 
omega-3 FAs significantly reduce cerebral infarction volume by around 40–50% 
and are associated with a drastic decrease in the neuroinflammatory response [70, 
71]. Interestingly, the long-term neurobehavioral recovery in experimental models 
of ischemic stroke is associated with neuroprotective effects of DHA on both gray 
and white matter [55]. It is noteworthy that one of these studies used a specific 
FOLE that is widely approved for clinical use [70].
9.2 Clinical studies
A limited number of omega-3 FAs interventional studies have been performed 
in SAH patients [13, 72–74]. The main characteristics and findings of these studies 
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are summarized in Table 1. Two studies utilized EPA and DHA, and only one study 
included a parenteral regimen. In total, 229 patients with SAH have received an 
omega-3 FAs intervention; most patients were surgically treated (n = 223). Although 
two studies were published as RCTs, one study had significant methodological short-
comings in the randomization process that conferred a high risk of selection bias [74]. 
While these preliminary clinical studies reported encouraging results (see Table 1), 
high-quality RCTs are needed to confirm the benefits of omega-3 FAs in SAH patients.
9.3 Safety considerations
Evidence obtained over more than two decades in other clinical fields indicates 
omega-3 FAs interventions are unlikely to lead to serious clinical harm in SAH 
patients [25, 59]. Nevertheless, parenteral administration of omega-3 FAs may raise 
some safety concerns. Total parenteral nutrition is associated with an increased 
risk of complications in critically ill patients [9]. Furthermore, administration of 
lipid emulsions (LEs) may cause fat overload syndrome; the amount of fat admin-
istered and LE infusion rate are the primary risk factors. In this regard, it should 
be emphasized that the therapeutic dose of FO (0.1–0.2 g of FO/kg/day) is about 
one order of magnitude lower than that of regular LE (0.7–1.5 g of fat/kg/day) [59]. 
Additionally, the plasma clearance rate is faster for FAs administered in FOLE than 
soybean oil-based LEs. These unique features contribute to the good safety profile 
of FOLE. Fish oil has been widely used as a component of total parenteral nutri-
tion and is associated with reduced rates of infection, shorter hospital stay, and 
decreased mortality, particularly in surgically treated patients [59].
Furthermore, isolated parenteral administration of FO has increasingly been 
used in pediatric patients with parenteral nutrition-associated liver disease 
(PNALD). Several case series published since 2006 have reported parenteral FO 
monotherapy (PFOM) remarkably improved clinical outcome of patients with 
PNALD [75]. Importantly, PFOM has demonstrated a good safety profile in these 
Reference Type of study Population, n Intervention Main result
Yoneda 
et al. [73]
Prospective, 
non-
randomized
n = 101
EPA = 73
Oral EPA: 1800 mg/
day × 10 postoperative 
(PO) days
Reduction in 
vasospasm 
and cerebral 
infarction
Yoneda 
et al. [74]
RCT n = 162
EPA = 81
Oral EPA: 2700 mg/
day × 30 PO days
Reduction in 
vasospasm 
and cerebral 
infarction
Nakagawa 
et al. [72]
Retrospective 
study
n = 100
EPA + DHA = 55
Oral EPA: 1860 mg/
day + oral DHA: 750 mg/
day × 90 PO days
Reduction in 
vasospasm 
and cerebral 
infarction
Saito et al. 
[13]
Pilot RCT n = 41
EPA + DHA = 20
Parenteral perioperative: 
5 days
Oral EPA: 1840 mg/
day + oral DHA: 1520 mg/
day × 8 weeks
No 
postoperative 
intracranial 
bleeding 
complications
Easy-to-
implement 
intervention
Table 1. 
Summary of the features and outcomes of clinical interventional studies in SAH patients.
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critically ill patients, even at FO doses up to 1.5 g FO/kg/day and overextended 
treatments beyond 4 weeks, well beyond the manufacturer’s recommendations.
The aim of replacement FO therapy in PNALD is obviously different to SAH 
patients. Parenteral administration of FO is intended to address key nutrient defi-
ciencies during the acute stage after SAH, and thus only short-term administration 
of a regular FO dose should be necessary. In fact, a 5-day parenteral perioperative 
regimen did not increase the occurrence of major postoperative complications in 19 
surgically treated SAH patients [13]. Thus, there is good quality evidence to warrant 
further clinical trials of parenteral pharmaconutrition as an integral component of 
interventions with omega-3 FAs in SAH patients.
10.  Role of inflammation resolution in the growth and rupture  
of intracranial aneurysms
The role of inflammation in the growth and rupture of intracranial aneurysms 
(IAs) has been increasingly recognized over the last few decades; however, the 
specific role of resolution of inflammation in IAs has not yet been considered [76]. 
Although the pathophysiology of atherosclerosis and the growth and rupture of IAs 
are distinct, both conditions are mediated by an underlying inflammatory process 
[77]. The progression of atherosclerotic plaques determines plaque morphology and 
the risk of rupture. The degree of macrophage infiltration plays a crucial role in the 
progression of atherosclerotic plaques. Interestingly, IAs have also been recently 
regarded as a macrophage-mediated inflammatory disease in which prostaglandin 
E2 and the master transcription factor NF-kB may be crucial drivers of inflam-
matory signals [78, 79]. It should be remembered that prostaglandin E2 is derived 
from the long-chain omega-6 FAs ARA and that EPA can inhibit the generation of 
eicosanoids from ARA and also downregulates the activity of NF-kB [25].
Atherosclerotic plaques readily incorporate omega-3 FAs, and a higher plaque 
EPA content is associated with a reduced number of foam cells and macrophages, as 
well as increased plaque stability, as determined by a well-formed fibrous cap [80]. 
Additionally, signs of defective resolution of inflammation have been identified in 
atherosclerotic plaques [81]. One major function of SPMs (particularly maresins) 
is to induce phenotypic conversion of macrophages, which decrease inflamma-
tion and promote tissue regeneration [16]. In animal models of atherosclerosis, a 
traditional Western high-fat diet disrupts the homeostasis of inflammation resolu-
tion by nutrigenetic modulation of the 12/15-LOX pathways, thereby inhibiting the 
generation of protective SPMs [81, 82]. These recent findings in atherosclerosis, 
particularly the involvement of docosanoids in vascular inflammation, provide 
biological plausibility that defective resolution of inflammation is implicated in the 
pathogenesis of IA growth and rupture.
Human beings evolved, and their genetic patterns were established on a diet with an 
omega-6/omega-3 FAs ratio of 1/1, whereas in current Western diets, this ratio is around 
16/1 [83]. Thus, this extreme nutritional imbalance in current Western diets should be 
seriously considered as a potential aggravating factor for the growth and rupture of 
IAs [48, 82]. This suggestion may appear somewhat counterintuitive considering the 
high prevalence of IAs with increased risk of rupture in the Japanese population, which 
has one of the highest dietary intakes of omega-3 FAs worldwide [48, 84]. However, 
nutritional deficiency of long-chain omega-3 FAs may not be the only factor associated 
with defective resolution of inflammation. Inter-individual and ethnic variations in the 
susceptibility to IA growth and rupture could be related to tissue-specific enzymatic 
deficiencies in the biosynthetic routes that regulate the resolution of inflammation. 
However, while defective resolution has already been associated with other chronic 
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inflammatory diseases, it is not yet known whether enzymatic deficiencies contribute to 
IA growth and rupture, and this novel hypothesis requires further investigation [85, 86].
11. Final remarks
The vital roles of EPA and DHA in the human body emphasize the evolutionary 
importance of maintaining efficient functional couplings between chemical and 
biological systems as well as between the vasculature and the brain [87]. Resolution 
of inflammation and endogenous neuroprotective signaling are interrelated processes 
that largely depend on EPA and DHA derivatives. This novel concept may open new 
avenues for public health interventions and innovative research in IAs and SAH.
Although nutrition has been traditionally viewed as a supportive measure, increas-
ing evidence strongly suggests that a more balanced dietary intake of omega-6 and 
omega-3 FAs may represent the most efficient means of improving the status of 
inflammation resolution at the population level [48, 82, 83]. This specific dietary 
recommendation could contribute to decrease the risk of IAs growth and rupture and 
the devastating consequences of SAH, along with other important health benefits.
The pathological significance of the loss of brain DHA after SAH has been 
widely ignored, even though strong preclinical evidence supports the hypothesis 
that the integrity of the neurovascular unit largely depends on high DHA enrich-
ment. This previously unrecognized pathophysiological process may significantly 
increase the risk of secondary brain injury following SAH.
The robust demonstration of the clinical efficacy of EPA in patients with chronic 
CV disease supports the encouraging results obtained in preliminary clinical studies 
of omega-3 FAs in SAH and warrants a large-scale RCT. It needs to be emphasized 
that DHA should always be included in neuroprotective interventions, as DHA 
plays an essential role in neural tissue and is the cornerstone for docosanoid genera-
tion. Parenteral pharmaconutrition with FO offers major clinical advantages for the 
treatment of SAH patients and should also be an integral component of omega-3 
FAs interventions during the acute stage of the disease.
The design of future RCTs of omega-3 FAs in SAH should bear in mind a potentially 
important factor. Clinical approaches that mainly focus on large-artery vasospasm may 
actually counteract the beneficial effects of omega-3 FAs and other neuroprotective 
interventions. The main rationale behind this seemingly paradoxical notion is based 
on both theoretical models and clinical perspectives [3, 31]. An unpublished subgroup 
analysis of our pilot pharmaconutrition trial of omega-3 FAs showed unexpected 
differences in the occurrence of cerebral infarction due to DCI between study centers, 
each of which had different clinical approaches to large-artery vasospasm [13]. In addi-
tion, a recently published observational study performed in the UK showed centers 
that screened for large-artery vasospasm using transcranial Doppler ultrasound (TCD) 
had poorer inhospital outcomes and similar rates of DCI diagnosis compared to centers 
that did not [88]. These results support the dissociation between large-artery vaso-
spasm and clinical outcome that has been observed in major phase 3 RCTs in SAH [8]. 
Therefore, reliance on a surrogate clinical endpoint such as large-artery vasospasm may 
lead to the adoption of useless or even harmful clinical approaches [88–91]. Indeed, 
some research centers in Europe do not include TCD ultrasound or endovascular rescue 
therapy in their treatment protocols for SAH patients [92].
Moreover, it would be clinically meaningful to determine if correlations exist 
between the omega-3 index and the concentrations of EPA and DHA as well as the 
status of inflammation resolution in the wall of ruptured and non-ruptured IAs. 
There may be a real opportunity for a readily implementable and low-cost therapy if 
the walls of IAs are as responsive to omega-3 FAs as atherosclerotic plaques.
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The interplay between omega-3 FAs and widely used drugs (aspirin and statins) 
that lead to the generation of longer-acting SPM R-epimers provides ample oppor-
tunities for future translational approaches in IAs and SAH. Indeed, combined 
therapies with omega-3 FAs and aspirin or statins could represent a viable, easy-to-
implement therapeutic strategy for patients with unruptured IAs.
Parenteral pharmaconutrition with FO could also be a clinically effective inter-
vention for perioperative neuroprotection for patients subjected to other surgeries 
at high risk of neurological injury, such as carotid endarterectomy, cardiac surgery, 
or diverse neurosurgical procedures.
In the future, new drug delivery systems capable of carrying synthetic analogues 
of SPMs could become a viable therapeutic strategy for patients with tissue-specific 
enzymatic deficiencies in the resolution pathways [93].
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